Skip to content

Study · Not a test of the peptide alone · 2017

4 results

An Audit of the Use of Gonadorelin Analogues to Prevent Recurrent Acute Symptoms in Patients with Acute Porphyria in the United Kingdom.

Schulenburg-Brand D, Gardiner T, Guppy S, Rees DC, Stein P, Barth J, Felicity Stewart M, Badminton M

JIMD reports21 Feb 2017Cited by 25 (Europe PMC)

PMID28220410 (opens in a new tab)PMCIDPMC5680288 (opens in a new tab)DOI10.1007/8904_2017_2 (opens in a new tab)PepBankPUB-28220410
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Gonadorelin (GnRH, LHRH).

  1. 01HumanNot a test of Gonadorelin (GnRH, LHRH) aloneObservational studySafety outcome

    In women with acute porphyria, the majority had oestrogen deficiency symptoms during gonadorelin analogue treatment.

    In plain wordsIn women with acute porphyria, most had symptoms of low oestrogen during treatment with gonadorelin analogue drugs.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    Not applicableOestrogen deficiency symptoms
    Study

    n = 20

    Outcome group
    Adverse events · Endocrine and hormones

    Source sentences

    Summary
    The majority of patients experienced oestrogen deficiency symptoms during treatment.
    1 context sentence
    Summary · context
    This audit surveyed the use of prophylactic GnA in the UK.Twenty female patients (who experienced between 2 and 45 acute attacks of porphyria requiring hospitalisation and treatment with human haemin prior to GnA prophylaxis) were included in the audit.

    In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).

  2. 02HumanNot a test of Gonadorelin (GnRH, LHRH) aloneObservational studySafety outcome

    In three women with acute porphyria, an acute attack occurred after the first dose of a gonadorelin analogue when timing with the menstrual cycle was not considered.

    In plain wordsIn three women with acute porphyria, an attack followed the first dose of a gonadorelin analogue when cycle timing was not considered.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    Not applicableAcute attack after first dose
    Study

    n = 20

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    In three patients in whom timing with the menstrual cycle was not considered, an acute attack occurred after initiation of the first dose.
    1 context sentence
    Summary · context
    This audit surveyed the use of prophylactic GnA in the UK.Twenty female patients (who experienced between 2 and 45 acute attacks of porphyria requiring hospitalisation and treatment with human haemin prior to GnA prophylaxis) were included in the audit.

    In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).

  3. 03HumanNot a test of Gonadorelin (GnRH, LHRH) aloneObservational studyEfficacy outcome

    In women with acute porphyria, half of the prescribed gonadorelin analogue prophylaxis courses gave some clinical benefit.

    In plain wordsIn women with acute porphyria, half of the courses of gonadorelin analogue drugs gave some benefit.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    Not applicableClinical benefit of prophylactic GnA courses
    Study

    n: not reported in source

    Outcome group
    Porphyria markers and attacks · Whole body

    Source sentences

    Summary
    Fifty percent of the prescribed courses of GnA resulted in a degree of clinical benefit.
    1 context sentence
    Summary · context
    This audit surveyed the use of prophylactic GnA in the UK.Twenty female patients (who experienced between 2 and 45 acute attacks of porphyria requiring hospitalisation and treatment with human haemin prior to GnA prophylaxis) were included in the audit.

    In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).

  4. 04HumanNot a test of Gonadorelin (GnRH, LHRH) aloneObservational studyEfficacy outcome

    In women with acute porphyria who benefited, acute attacks fell from between 3 and 20 before to between 0 and 6 during gonadorelin analogue treatment.

    In plain wordsIn women with acute porphyria who benefited, attacks became less frequent during treatment with gonadorelin analogue drugs.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    DecreaseAcute attacks before and during GnA treatment
    Study

    n: not reported in source

    Outcome group
    Porphyria markers and attacks · Whole body

    Source sentences

    Summary
    This successfully treated group experienced between 3 and 20 acute attacks prior to and between 0 and 6 acute attacks during GnA treatment
    1 context sentence
    Summary · context
    This audit surveyed the use of prophylactic GnA in the UK.Twenty female patients (who experienced between 2 and 45 acute attacks of porphyria requiring hospitalisation and treatment with human haemin prior to GnA prophylaxis) were included in the audit.

    In this study, Gonadorelin (GnRH, LHRH) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Gonadorelin (GnRH, LHRH).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.